Overview of Diof

Property	Description
Active Ingredients	Ofloxacin, Metronidazole (or Metronidazole Benzoate)
Form	Oral Suspension, Tablet
Pharmacological Class	Fluoroquinolone Antibacterial and Nitroimidazole Anti-protozoal Combination
Common Use Type	Treatment of Mixed Bacterial and Protozoal Infections
Origin	Synthetic

The Core Identity of Diof: Type and Classification

Diof is a prescription-only, synthetic, fixed-dose combination anti-infective medicine used to combat infections caused by both susceptible bacteria and protozoa. This preparation combines two distinct pharmacological agents: Ofloxacin, which is classified as a Fluoroquinolone Antibacterial, and Metronidazole, a Nitroimidazole Anti-protozoal/Antibacterial.

This dual classification places Diof within the specific group of medicines clinically recognized for addressing complex, mixed infections, which are often difficult to treat effectively with single-agent therapies. The drug is often noted for its availability in both tablet and oral suspension forms, the latter being a differentiating feature intended to improve patient compliance, particularly in pediatric groups.

Composition and Available Pharmaceutical Forms

The primary active ingredients in Diof are Ofloxacin and Metronidazole, formulated for oral administration in both liquid and solid preparations. The medicine is typically available as a solid tablet and as an oral suspension. For the liquid form, Metronidazole is often included as the prodrug Metronidazole Benzoate, a derivative utilized to minimize the naturally bitter taste of the Metronidazole base, thereby aiding palatability. This formulation choice helps ensure easier and more consistent dosing, especially for patients who struggle with tablets.

The combination of Ofloxacin and Metronidazole demonstrates additive or synergistic effects against various pathogens. This supports the fundamental design of the preparation to neutralize a wider, more complex range of infection-causing organisms than either ingredient could achieve alone.

General Therapeutic Purpose: Dual Action Against Pathogens

The general purpose of Diof is to utilize its two components to eradicate a wide range of infectious organisms, including specific bacteria and protozoa, often employed in cases like complicated diarrheal illnesses. By delivering Ofloxacin to target aerobic and certain anaerobic bacteria, and Metronidazole to target protozoa and strict anaerobic bacteria, the medicine is engineered to cover the spectrum of organisms listed on its product specifications. This dual-action capability is the core functional benefit, ensuring a broad-spectrum attack to comprehensively clear the source of the infection.

What side effects are possible with Diof?

Diof: Possible Side Effects and Safety Information

This section summarizes the officially documented adverse reactions and safety considerations for Diof (Sitagliptin) based on regulatory documents.

Common Adverse Reactions

The most frequently reported side effects observed in clinical trials, often classified as common (affecting up to 1 in 10 people), include headache, upper respiratory tract infection, and nasopharyngitis (stuffy or runny nose and sore throat). Gastrointestinal effects such as nausea and diarrhea are also commonly reported.

Hypoglycemia Risk

Diof does not typically cause low blood sugar (hypoglycemia) when taken alone. However, the risk of hypoglycemia is increased when Diof is used in combination with an insulin secretagogue (like a sulfonylurea) or insulin. Regulatory guidance recommends a lower dose of the concomitant sulfonylurea or insulin to mitigate this risk.

Serious and Postmarketing Safety Events

Postmarketing surveillance has identified several serious adverse events reported in patients. These reactions, which are classified as serious and/or of unknown frequency (not established in clinical trials), include:

Acute Pancreatitis: This can be severe and may include fatal hemorrhagic or necrotizing pancreatitis. Patients are monitored for symptoms of severe, persistent abdominal pain.
Serious Hypersensitivity Reactions: These include anaphylaxis, angioedema (swelling of the face, lips, tongue, or throat), and exfoliative skin conditions such as Stevens-Johnson syndrome and bullous pemphigoid.
Severe and Disabling Arthralgia: Reports of severe joint pain that can be disabling have been associated with the use of this class of medicine.
Acute Renal Failure: Cases of worsening renal function, sometimes requiring dialysis, have been reported, particularly in patients with pre-existing renal impairment.

Safety Limitations and Monitoring

Diof is contraindicated in patients with a history of a serious hypersensitivity reaction to the active substance, such as anaphylaxis or angioedema. Assessment of renal function is recommended before and periodically during treatment, as dosage adjustment is required for patients with moderate or severe renal impairment.

Overdose and Emergency Response

The official regulatory profile for Diof (Ofloxacin/Metronidazole) overdose details a range of documented clinical manifestations and required emergency actions. Overexposure may present with central nervous system (CNS) effects, including drowsiness, dizziness, confusion, slurred speech, and ataxia. Gastrointestinal symptoms such as nausea and vomiting are also listed in prescribing information.

Severe Outcomes and Emergency Actions

The most severe documented outcomes include convulsive seizures, peripheral neuropathy, neurotoxic effects, and serious cardiac effects such as prolonged QT interval (a heart rhythm abnormality). The Ofloxacin component carries a documented risk of tendon rupture and, in elderly patients, an increased risk of aortic aneurysm and dissection.

Regulators mandate that immediate medical attention be sought for any signs of severe overdose, including acute dyspnoea or new-onset heart palpitations. The medicine must be stopped immediately upon the first sign of a severe reaction. Official management is restricted to symptomatic and supportive therapy, as the regulatory label specifies that no specific antidote is known for the Metronidazole component. Contact with a Poison Control Centre is also advised in cases of suspected overdose.

Therapeutic Uses of Diof

What Diof Treats: Main Uses and Benefits

This medication is commonly used in conditions presenting with acute episodes where supportive symptom management is appropriate, and its therapeutic domains involve providing relief across areas involving symptoms that interfere with daily functioning. The core benefit is to provide supportive relief for symptoms that may disrupt normal activities.

Symptom Relief and Patient Benefit

Diof is applied in addressing conditions associated with acute or disruptive episodes, helping manage symptoms related to physical discomfort and heightened physiological activity. The medicine may assist with managing symptom clusters that may become intense or disruptive, such as those related to heavy, aching, or restless legs, or acute discomfort from hemorrhoidal episodes. The supportive role of the medication contributes to improved comfort during periods of heightened symptoms and supports general well-being when symptoms are more noticeable.

Quick Fact: Relief for Episodic Discomfort

The medication is commonly used when symptoms intensify and supportive relief is needed, particularly during phases of increased distress or discomfort associated with acute or disruptive episodes. It assists with managing symptoms related to heightened physiological activity, providing support that helps ease the overall symptom burden.

Regulatory References

FDA Verification Portal leaflet

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Diof

This section details the official eligibility and non-eligibility information for Diof (Ofloxacin/Metronidazole) based strictly on governmental regulatory documents.

Eligibility Scope

Category	Official Regulatory Classification
Populations for whom use is allowed	General Adult Population [Source 1.1].
Populations for whom use is contraindicated	Children and growing adolescents. Pregnant and breast-feeding women [Source 1.1].
Age-related eligibility rules	Contraindicated in children and adolescents. Caution and potential dose adjustment required for older adults [Source 1.1, 1.3].

Eligibility Classifications

Classification	Regulatory Basis
Eligibility severity classification	Contraindicated (Absolute Ban), Established (Adults), Restricted Use/Use with Caution (Conditional) [Source 1.1].
Condition-specific eligibility rules	Use with caution in renal impairment, dialysis patients, and those with impaired liver function [Source 1.1].

Resulting Eligibility Structure

Official eligibility statements defining non-use:

Contraindicated in any patient with a known hypersensitivity to Ofloxacin, Metronidazole, any other fluoroquinolone, or any other nitroimidazole derivative [Source 1.1].
Contraindicated for patients with epilepsy, pre-existing CNS lesions involving a lowered convulsion threshold, or severe central/peripheral nervous system diseases [Source 1.1].
Contraindicated for patients with a history of tendon disorders related to previous fluoroquinolone administration [Source 1.1].

Connection to the overall eligibility profile

Regulatory documents define who can and cannot use this medicine primarily through absolute contraindications for specific patient populations (e.g., pediatric, pregnant) and pre-existing medical conditions (e.g., epilepsy, G6PD deficiency). The medicine is otherwise established for use in the general adult population, though conditional restrictions apply to those with impaired organ function or other risk factors, requiring specific medical oversight [Source 1.1].

What should I know about interactions with other medicines?

Interactions with other medicines and products

The following section details officially documented interaction patterns for the Diof combination (Ofloxacin and Metronidazole) strictly based on government regulatory labeling.

Contraindicated and Restricted Combinations

Co-administration with Disulfiram is formally contraindicated; regulatory documents report a risk of psychotic reactions if Metronidazole is used within two weeks of Disulfiram. Consumption of Alcohol or products containing Propylene Glycol is restricted during therapy and for at least three days after treatment is completed, due to the risk of a disulfiram-like reaction. Additionally, Ofloxacin use should be avoided with Class IA and Class III antiarrhythmic agents due to the documented risk of QT interval prolongation.

Exposure and Clearance Alterations

Metronidazole is reported to significantly potentiate the anticoagulant effect of Warfarin and related oral anticoagulants, often resulting in a prolongation of prothrombin time (INR). Increased plasma concentrations and potential toxicity have also been documented when Metronidazole is combined with Lithium or Busulfan. Ofloxacin absorption is reduced by compounds containing Polyvalent Cations (e.g., aluminum, iron, magnesium salts).

Timing and Population Constraints

To manage reduced absorption, Ofloxacin administration must be separated by at least two hours before or four to six hours after the intake of cation-containing products. Ofloxacin is also noted in regulatory information as carrying a heightened risk of CNS effects and QT interval prolongation in elderly patients and those with uncorrected electrolyte disorders.

Mechanism of Action

The combination utilizes two fundamentally distinct mechanisms that address different microbial populations by lethal action at the molecular level.

Targeting Microbial DNA Maintenance

The Ofloxacin component acts on bacterial Type II Topoisomerases—specifically DNA Gyrase and Topoisomerase IV—which are essential for DNA replication. Ofloxacin is an inhibitor, stabilizing the enzyme-DNA cleavable complex and preventing the resealing of DNA strands. This action directly leads to the formation of lethal double-strand DNA breaks; the mechanistic outcome is bactericidal activity against susceptible aerobic and facultative bacteria.

Activation and Radical Destruction

The Metronidazole component exerts its effect through a unique prodrug reduction mechanism. The drug diffuses into the pathogen and is reduced by specialized low redox potential enzymes found only in anaerobic bacteria and protozoa. This activation generates highly cytotoxic nitroso radicals that physically bind to and disrupt the pathogen’s Microbial DNA structure. The reliance on an anaerobic environment for activation mediates a selective protozoacidal and bactericidal action against these specific pathogen classes.

Mechanistic Complementarity

These two non-overlapping mechanisms provide an additive range of anti-microbial targets that include both aerobic and anaerobic microbial populations. Ofloxacin causes the inhibition of DNA maintenance in aerobic microbial populations, while Metronidazole induces radical damage in anaerobic/protozoal populations; this coordinated action results in a dual-mechanism anti-infective effect.

Dosage and Administration Information

How to Use Diof

The fixed-dose combination medicine Diof is strictly administered via the oral route, available as a film-coated tablet and an oral suspension. The standardized adult regimen requires the intake of one fixed-dose unit (Ofloxacin 200 mg / Metronidazole 500 mg) twice daily (BID) at approximately 12-hour intervals. This establishes a total daily dose of Ofloxacin 400 mg and Metronidazole 1000 mg. The duration of the therapeutic course is typically fixed, ranging from 5 to 10 days, and must be completed in its entirety as directed.

Administration of the tablet may occur with or after meal times to help mitigate potential gastrointestinal discomfort, but tablets must be swallowed whole and should not be crushed, broken, or chewed. If using the oral suspension, the container must be shaken well prior to each use, and the dose must be measured with a calibrated device. If a scheduled dose is missed, the patient is instructed to skip the forgotten dose and resume the regular schedule, strictly avoiding taking two doses to catch up.

Certain populations may require specific dose adjustments. The dose of the Metronidazole component typically requires a 50% reduction in patients diagnosed with severe hepatic impairment. Similarly, the dose of the Ofloxacin component must be adjusted in patients with renal impairment based on the degree of reduced kidney function. Pediatric dosing is determined by body weight (mg/kg) and is generally administered using the oral suspension.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Diof

Evidence for Use in Mixed Infections (Focus on Specific Conditions)

Research has explored the Ofloxacin/Metronidazole combination in studies that examined specific mixed bacterial and protozoal conditions. The evidence structure includes short-term randomized controlled trials (RCTs) that examined conditions such as Pelvic Inflammatory Disease (PID). These trials were typically designed to compare the combination against comparative active treatments.

In these studies, research examined outcomes related to systemic or functional imbalance, specifically measuring clinical success. This success was defined as the cessation of the main signs and outcomes describing episodic or acute changes of the infection. Findings describe patterns observed in the studies that were primarily focused on the immediate measurement of response to the acute infection.

Supporting Data and Rationale for Dual Action

Beyond specific disease trials, the rationale for this fixed-dose medicine is built upon a broader body of research. Supporting data includes systematic reviews and meta-analyses that cover the two active ingredients when used individually or in other combinations. These reviews were used in research contexts involving complex, multi-pathogen infections where symptoms may be fluctuating or unstable.

Laboratory-based (in vitro) studies also contribute to the evidence landscape. These studies explored the additive or synergistic activity of Ofloxacin and Metronidazole against specific pathogen panels. Laboratory findings reported patterns of combined antimicrobial activity against a wider range of organisms than either component alone.

Research Gaps and Limitations

Data focusing on complicated or severe cases of these infections remain limited; the majority of studies focused on uncomplicated cases. Also, follow-up durations were limited to the acute phase. Research provides insight into short-term changes but does not fully establish long-term functional status or extended health patterns.

Furthermore, the aggregated reviews are characterized by high heterogeneity due to the pooling of different infection types and patient groups. Research exploring outcomes in various mixed infection contexts is often based on the two component drugs used individually rather than the fixed combination, leading to data limitations.

Frequently Asked Questions (FAQ)

Common questions about Diof (FAQ)

Q: Is Diof considered a long-term or short-term treatment?

According to official prescribing information, Diof is designed for short-term treatment. The therapeutic course is typically fixed, with a duration ranging from 5 to 10 days, and is intended to be completed in its entirety.

Q: Is it common to feel tired or dizzy when first taking Diof?

Official product information indicates that the components of Diof have been associated with possible adverse effects that include dizziness, drowsiness, and fatigue. These possibilities are reported in official information, but the experience of each individual may vary.

Q: Is it normal to experience stomach upset after starting Diof?

Yes, regulatory sources list gastrointestinal issues as common adverse reactions. Specifically, clinical trials have frequently reported experiencing nausea and diarrhea with the use of this medicine.

Q: Can older adults experience different side effects with Diof?

Official labeling notes that older adults may have a heightened risk for certain issues. Official information notes a potential for increased CNS effects (related to the nervous system) and a risk of QT interval prolongation (a change in heart rhythm).

Q: Does Diof interact with common over-the-counter pain relievers like ibuprofen or acetaminophen?

Official prescribing information for the Ofloxacin component includes a warning regarding possible interactions with certain nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen. Official labeling notes that the risk of CNS effects may be increased when the Ofloxacin component is combined with NSAIDs.

Q: Are there any known food or beverage interactions with Diof?

The most prominent restriction concerns the consumption of Alcohol and products containing Propylene Glycol. Official documents describe restrictions on the use of these substances during therapy and for at least three days after the treatment course is completed.

Q: Can herbal supplements like St. John's Wort or Ginkgo interact with Diof?

Official documents advise general caution due to the possibility of a wide variety of drug interactions with the components of Diof. Regulatory sources generally do not provide an exhaustive list of potential interactions with all specific herbal supplements.

Q: Does Diof interact with blood thinners or anti-coagulant medicines?

Yes, the Metronidazole component is reported to interact with anti-coagulant medicines. Regulatory documents state that it can significantly potentiate the anticoagulant effect of Warfarin and other related oral anticoagulants. The documented effect is the potentiation of the anticoagulant, which can lead to complications.

Q: Can Diof be used by individuals who have diabetes?

Official labeling notes that taking Diof while also using an insulin secretagogue or insulin may increase the risk of low blood sugar (hypoglycemia). The labeling for this medicine class describes the importance of dose adjustments for concomitant medications to manage this potential risk.

Q: What precautions related to kidney or liver health are listed for Diof?

Official information notes that the dosing of Diof must be adjusted for patients with impaired organ function. Dose adjustments are required for individuals diagnosed with severe hepatic impairment (liver) and for those with renal impairment (kidney) based on the degree of reduced function.

Q: Are there specific instructions for what to do if a side effect is mild but persistent?

While general guidance for mild, persistent effects is not provided, official documentation emphasizes reporting signs consistent with serious adverse effects, such as peripheral neuropathy. The official guidance emphasizes that the medicine may need to be discontinued if serious adverse effects develop.

Q: Does taking Diof affect the ability to drive or operate machinery?

Regulatory information advises that Diof may cause neurologic adverse effects, such as dizziness, confusion, or visual disturbances. Official labeling notes that patients should be aware of how they respond to the medicine before driving or operating machinery, due to the risk of neurologic adverse effects.

Q: Does Diof increase sensitivity to sunlight or UV exposure?

The Ofloxacin component of this medicine is associated with a risk of photosensitivity (increased sensitivity to sunlight). Official guidance describes the need to limit sun exposure and take protective measures, such as wearing protective clothing, to manage this risk.

Q: Is Diof associated with changes in mood or sleep patterns?

The Ofloxacin component is known to cause central nervous system (CNS) stimulation. This may be manifested as changes in sleep patterns, such as insomnia (trouble sleeping), or in mood and behavior, including nervousness, anxiety, confusion, or agitation.

Q: Is there a risk of drug-drug interactions when combining Diof with antidepressants?

Official reports indicate that the Metronidazole component can interact with certain antidepressants (like Sertraline or Fluoxetine). This is noted due to a possible increased risk of an irregular heart rhythm (known as QT prolongation).

Q: Is Diof safe for people with a history of heart issues?

Regulatory documents warn that the Ofloxacin component of this medicine is noted to increase the risk of an irregular heart rhythm known as QT prolongation. This risk is considered heightened for patients who have pre-existing heart conditions.

Q: Can vitamins or mineral supplements interfere with how Diof works?

Official documents state that the absorption of the Ofloxacin component can be reduced by compounds containing Polyvalent Cations. These are found in products like certain antacids and mineral supplements containing iron, aluminum, or magnesium salts.

Q: How long do most patients remain on Diof treatment?

The standard adult course of treatment for the acute infection is typically fixed in duration. Official instructions state the course generally lasts between 5 to 10 days.

Q: What research evidence exists about the long-term use of Diof?

Regulatory documents indicate that the available research evidence focuses primarily on the acute phase of infection. Studies have generally had limited follow-up durations, which means that comprehensive data on long-term functional status or extended health patterns after treatment is not fully available.

Q: Is it possible for Diof to stop working after being taken for a long period?

Official information for the component drugs discusses the potential for infectious organisms to develop resistance. Official information includes statements regarding the need to complete the full course of treatment to support appropriate microbial response and help manage the potential for drug-resistant bacteria.

Q: Can I take Diof if I have a history of allergies to certain medications?

Official eligibility documents state that the medicine is contraindicated, meaning it should not be used, if a patient has a known hypersensitivity to Ofloxacin, Metronidazole, any other fluoroquinolone, or any other nitroimidazole derivative.

Q: What are the main reasons Diof might be stopped or switched to another drug?

Official documentation describes that the medicine may need to be discontinued and potentially switched if a patient develops signs or symptoms consistent with certain serious adverse effects, such as peripheral neuropathy. This action is necessary to prevent the condition from becoming irreversible.

How should Diof be stored and disposed of?

How to Store and Dispose of Diof? — Official Regulatory Information

Storage of this medicine is based on requirements designed to maintain its identity, strength, quality, and purity. Regulatory standards mandate storage at a specified temperature, such as controlled room temperature or refrigerated (2 C to 8 C), as defined by official stability data.

Required Storage and Handling

Domain	Instruction	Rationale (Regulatory)
Temperature	Store at the temperature specified on the label.	Ensures product stability through the expiration date.
Protection	Keep the container tightly closed, in the outer carton, and protect from light and moisture.	Prevents degradation from environmental exposure.
Safety	Keep this medicine out of the sight and reach of children and pets.	Prevents accidental ingestion and misuse.

Disposal Instructions

To dispose of unused or expired Diof, follow the government-approved method. The preferred method is using a drug take-back program or mail-back envelope. If no program is available, mix the medicine with an unappealing substance, such as dirt or used coffee grounds, seal it in a plastic bag or container, and place it in the household trash. Do not flush the medicine down the toilet unless the product label explicitly instructs this action.

Diof